Berry Announces Fourth Quarter and Fiscal Year 2024 Results
Strategy Update – New Berry
- Successful completion of the spin of Berry’s Health, Hygiene and Specialties Global Nonwovens and Films Business (‘HHNF’) and merger with Glatfelter Corporation in early November
- New Berry emerges as a global leader of consumer-focused packaging solutions with enhanced stability of earnings, free cash flow and growth
Fourth Quarter Highlights
-
GAAP: Net sales of
$3.2 billion ; Operating income of$269 million ; Earnings per share of$1.26 -
Non-GAAP: Operating EBITDA of
$546 million ; Adjusted earnings per share of$2.27 - Organic volume growth of +2% (1% including HHNF)
Fiscal Year Highlights
-
GAAP: Net sales of
$12.3 billion ; Operating income of$937 million ; Earnings per share of$4.38 -
Non-GAAP: Operating EBITDA of
$2,045 million ; Adjusted earnings per share of$7.62 - 12th consecutive year of Adjusted earnings per share growth
- Achieved adjusted earnings per share and free cash flow targeted guidance
-
Returned
$260 million to shareholders ($120 million via share repurchases and$140 million in dividends) - Achieved leverage target goal of 3.5x
As a result of our team’s outstanding performance we ended fiscal 2024 on a strong note, achieving 2% organic volume growth, excluding HHNF, in our underlying businesses and over 6% earnings per share growth in the second half. We also reached our leverage goal of 3.5x, the lowest in the company’s history. Our lean transformation and customer excellence initiatives contributed to positive volumes again this quarter, as we continue to navigate a challenging consumer environment.
Looking ahead to fiscal 2025, we anticipate continued low-single digit volume growth as demonstrated in the second half and the same strong adjusted free cash flow we have consistently delivered. We are confident in the strength and resilience of our portfolio, as reflected by the Board’s decision to raise our dividend by nearly 13% following last year’s 10% increase. As we move forward we intend to deliver enhanced value to our shareholders by continuing to focus on three key objectives: accelerating organic growth, increasing margins from improved operations, and deleveraging.”
Key Financials (1)
|
|
Reported |
|
Fiscal Year |
Reported |
|||
GAAP results |
2024 |
2023 |
Δ% |
|
2024 |
2023 |
Δ% |
|
Net sales |
|
|
|
3% |
|
|
|
(3%) |
Operating income |
|
269 |
301 |
(11%) |
|
937 |
1,079 |
(13%) |
EPS (diluted) |
|
1.26 |
1.55 |
(19%) |
|
4.38 |
4.95 |
(12%) |
|
|
Reported |
Comparable |
Fiscal Year |
Reported |
Comparable |
||
Adjusted non-GAAP results |
2024 |
2023 |
Δ% |
Δ% |
2024 |
2023 |
Δ% |
Δ% |
Operating EBITDA |
546 |
547 |
flat |
(1%) |
2,045 |
2,053 |
flat |
(1%) |
Adjusted EPS (diluted) |
2.27 |
2.28 |
flat |
(1%) |
7.62 |
7.42 |
3% |
2% |
(1) |
Adjusted non-GAAP results exclude items not considered to be ongoing operations. In addition, comparable change % excludes the impacts of foreign currency, acquisitions, and recent divestitures. Further details related to non-GAAP measures and reconciliations can be found under our “Non-GAAP Financial Measures and Estimates” section and in reconciliation tables in this release. In millions of USD, except per share data. |
Financial Results – Fourth Quarter 2024
Consolidated Overview
Net sales increased 3% to
Operating income decreased by 11% compared to the prior year quarter, totaling
Net sales were in line with the prior year quarter at
Operating income decreased by 14% to
Net sales increased 7% to
Operating income increased 32% to
Flexibles
Net sales increased by 2%, reaching
Operating income decreased by 29% primarily driven by higher restructuring and selling, general and administrative costs along with negative price cost spread primarily related to a prior year timing tailwind, partially offset by 1% volume growth.
Health, Hygiene & Specialties
Net sales increased by 2% totaling
Operating income decreased
Cash Returns to Shareholders
Berry generates significant cash flow and is committed to returning capital to shareholders. This annual cash flow provides substantial capacity to simultaneously reinvest in the business for organic growth, pay down debt, pursue bolt-on acquisitions, and return cash to shareholders through a compelling dividend as well as share repurchases. The Company’s ending leverage at year end was 3.5x. We expect to further reduce leverage in fiscal 2025, while also returning cash to shareholders during the year, through continued share repurchases and dividends, subject to market conditions, available cash on hand and cash needs, overall financial condition, and other factors considered relevant by our Board of Directors.
Dividend and Share Repurchases
As previously announced, Berry’s Board of Directors increased the quarterly cash dividend by nearly 13% to
Fiscal Year 2025 Guidance
-
Adjusted earnings per share range of
$6.10-$6.60 (Fiscal 2024 comparable~$6.00 ) -
Cash flow from operations of
$1.125-$1.225 billion ; free cash flow of$600-$700 million - Committed to further debt reduction along with return of capital to shareholders
Merger with Amcor Plc and Conference Call Information
In a separate press release issued this morning, Berry announced that it has entered into a definitive merger agreement to combine with Amcor Plc in an all-stock transaction.
Berry and
All other countries: +1 646 307-1963 (this is not a toll-free number)
Conference ID 3964921
Access to the webcast, located here, https://events.q4inc.com/attendee/157829806 and supporting materials will be available via the Investors section of each company’s website at https://ir.berryglobal.com/financials and www.Amcor.com. A webcast replay will be available at the conclusion of the call.
As a result, Berry will no longer host its previously planned quarterly conference call at
About Berry
At
Non-GAAP Financial Measures and Estimates
This press release includes non-GAAP financial measures such as operating EBITDA, Adjusted operating income, Adjusted earnings per share (or adjusted EPS), free cash flow, and comparable basis net sales, comparable adjusted EPS and comparable operating EBITDA. A reconciliation of these non-GAAP financial measures to comparable measures determined in accordance with accounting principles generally accepted in
Forward Looking Statements
Statements in this release that are not historical, including statements relating to the expected future performance of the Company as well as estimates and statements as to the expected timing, completion and effects of the proposed transaction between Berry and Glatfelter, are considered “forward looking” within the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements because they contain words such as “believes,” “expects,” “may,” “will,” “should,” “would,” “could,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” “projects,” “outlook,” “anticipates” or “looking forward,” or similar expressions that relate to our strategy, plans, intentions, or expectations. All statements we make relating to estimates and statements about the expected timing and structure of the proposed transaction, the ability of the parties to complete the proposed transaction, benefits of the Glatfelter transaction, including future financial and operating results, executive and Board transition considerations, the combined company’s plans, objectives, expectations and intentions, and other statements that are not historical facts, as well as statements we make relating to our estimated and projected earnings, margins, costs, expenditures, cash flows, growth rates, and financial results or to our expectations regarding future industry trends are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments.
Our actual results may differ materially from those that we expected due to a variety of factors, including without limitation: (1) risks associated with our substantial indebtedness and debt service; (2) changes in prices and availability of resin and other raw materials and our ability to pass on changes in raw material prices to our customers on a timely basis; (3) risks related to acquisitions or divestitures and integration of acquired businesses and their operations, and realization of anticipated cost savings and synergies; (4) risks related to international business, including transactional and translational foreign currency exchange rate risk and the risks of compliance with applicable export controls, sanctions, anti-corruption laws and regulations; (5) increases in the cost of compliance with laws and regulations, including environmental, safety, and climate change laws and regulations; (6) labor issues, including the potential labor shortages, shutdowns or strikes, or the failure to renew effective bargaining agreements; (7) risks related to disruptions in the overall global economy, persistent inflation, supply chain disruptions, and the financial markets that may adversely impact our business; (8) risk of catastrophic loss of one of our key manufacturing facilities, natural disasters, and other unplanned business interruptions; (9) risks related to weather-related events and longer-term climate change patterns; (10) risks related to the failure of, inadequacy of, or attacks on our information technology systems and infrastructure; (11) risks that our restructuring programs may entail greater implementation costs or result in lower cost savings than anticipated; (12) risks related to future write-offs of substantial goodwill; (13) risks of competition, including foreign competition, in our existing and future markets; (14) risks related to market conditions associated with our share repurchase program; (15) risks related to market disruptions and increased market volatility; (16) the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed transaction; (17) the risk that Glatfelter shareholders may not approve the transaction proposals; (18) the risk that the necessary regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated or may be delayed; (19) risks that any of the other closing conditions to the proposed transaction may not be satisfied in a timely manner; (20) risks that the anticipated tax treatment of the proposed transaction is not obtained; (21) risks related to potential litigation brought in connection with the proposed transaction; (22) uncertainties as to the timing of the consummation of the proposed transaction; (23) risks and costs related to the implementation of the separation of the Berry Spinco from Berry., including timing anticipated to complete the separation, any changes to the configuration of the businesses included in the separation if implemented, as well as unexpected costs, charges or expenses resulting from the proposed transaction; (24) the risk that the integration of the combined companies is more difficult, time consuming or costly than expected; (25) risks related to financial community and rating agency perceptions of each of Berry and Glatfelter and its business, operations, financial condition and the industry in which they operate; (26) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (27) failure to realize the benefits expected from the proposed transaction; (28) the effects of the announcement, pendency or completion of the proposed transaction on the ability of the parties to retain customers and retain and hire key personnel and maintain relationships with their counterparties, and on their operating results and businesses generally; and (29) the other factors and uncertainties discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K and subsequent filings with the
Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of the proposed transaction between Berry and Glatfelter. In connection with the proposed transaction, Berry and Glatfelter intend to file relevant materials with the
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to sell, subscribe for or buy, or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, sale or solicitation would be unlawful, prior to registration or qualification under the securities laws of any such jurisdiction. No offer or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.
Participants in Solicitation
Berry and its directors and executive officers, and Glatfelter and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the holders of Glatfelter capital stock and/or the offering of securities in respect of the proposed transaction. Information about the directors and executive officers of Berry, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth under the caption “Security Ownership of Beneficial Owners and Management” in the definitive proxy statement for Berry’s 2024 Annual Meeting of Stockholders, which was filed with the
Consolidated Statements of Income (Unaudited) |
|||||||||||
|
Quarterly Period Ended |
|
Fiscal Year Ended |
||||||||
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
||||
Net sales |
$ |
3,168 |
|
$ |
3,087 |
|
$ |
12,258 |
|
$ |
12,664 |
Costs and expenses: |
|
|
|
|
|
|
|
||||
Cost of goods sold |
|
2,557 |
|
|
2,481 |
|
|
10,005 |
|
|
10,354 |
Selling, general and administrative |
|
228 |
|
|
215 |
|
|
892 |
|
|
886 |
Amortization of intangibles |
|
57 |
|
|
62 |
|
|
234 |
|
|
243 |
Business consolidation and other activities |
|
52 |
|
|
28 |
|
|
190 |
|
|
102 |
Operating income |
|
269 |
|
|
301 |
|
|
937 |
|
|
1,079 |
Other expense |
|
7 |
|
|
18 |
|
|
15 |
|
|
31 |
Interest expense, net |
|
86 |
|
|
78 |
|
|
311 |
|
|
306 |
Income before income taxes |
|
176 |
|
|
205 |
|
|
611 |
|
|
742 |
Income tax expense |
|
28 |
|
|
19 |
|
|
95 |
|
|
133 |
Net income |
$ |
148 |
|
$ |
186 |
|
$ |
516 |
|
$ |
609 |
|
|
|
|
|
|
|
|
||||
Basic net income per share |
$ |
1.29 |
|
$ |
1.59 |
$ |
4.48 |
|
$ |
5.07 |
|
Diluted net income per share |
|
1.26 |
|
|
1.55 |
|
4.38 |
|
|
4.95 |
|
|
|
|
|
|
|
|
|
||||
Outstanding weighted average shares (in millions |
|
|
|
|
|
|
|
||||
Basic |
|
114.6 |
|
|
117.3 |
|
|
115.1 |
|
|
120.1 |
Diluted |
|
117.4 |
|
|
120.2 |
|
|
117.7 |
|
|
123.0 |
Condensed Consolidated Balance Sheets (Unaudited) |
||||
(in millions of USD) |
|
|
||
Cash and cash equivalents |
$ |
1,095 |
$ |
1,203 |
Accounts receivable |
|
1,604 |
|
1,568 |
Inventories |
|
1,624 |
|
1,557 |
Other current assets |
|
244 |
|
205 |
Property, plant, and equipment |
|
4,575 |
|
4,576 |
|
|
7,464 |
|
7,478 |
Total assets |
$ |
16,606 |
$ |
16,587 |
Current liabilities, excluding current debt |
|
2,855 |
|
2,703 |
Current and long-term debt |
|
8,315 |
|
8,980 |
Other long-term liabilities |
|
1,828 |
|
1,688 |
Stockholders’ equity |
|
3,608 |
|
3,216 |
Total liabilities and stockholders' equity |
$ |
16,606 |
$ |
16,587 |
|
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|||||||
|
Fiscal Year Ended |
||||||
(in millions of USD) |
|
|
|
||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
516 |
|
|
$ |
609 |
|
Depreciation |
|
623 |
|
|
|
575 |
|
Amortization of intangibles |
|
234 |
|
|
|
243 |
|
Non-cash interest, net |
|
(79 |
) |
|
|
(61 |
) |
Share-based compensation expense |
|
46 |
|
|
|
42 |
|
Deferred income tax |
|
(96 |
) |
|
|
(117 |
) |
Loss on divestitures |
|
57 |
|
|
|
- |
|
Settlement of derivatives |
|
26 |
|
|
|
36 |
|
Other non-cash operating activities, net |
|
22 |
|
|
|
22 |
|
Changes in working capital |
|
56 |
|
|
|
266 |
|
Net cash from operating activities |
|
1,405 |
|
|
|
1,615 |
|
|
|
|
|
||||
Cash flows from investing activities: |
|
|
|
||||
Additions to property, plant, and equipment, net |
|
(551 |
) |
|
|
(689 |
) |
Acquisitions, divestitures, and other activities |
|
(21 |
) |
|
|
(87 |
) |
Net cash from investing activities |
|
(572 |
) |
|
|
(776 |
) |
|
|
|
|
||||
Cash flows from financing activities: |
|
|
|
||||
Repayments on long-term borrowings |
|
(3,884 |
) |
|
|
(869 |
) |
Proceeds from long-term borrowings |
|
3,150 |
|
|
|
496 |
|
Repurchase of common stock |
|
(120 |
) |
|
|
(601 |
) |
Proceeds from issuance of common stock |
|
48 |
|
|
|
36 |
|
Dividends paid |
|
(139 |
) |
|
|
(127 |
) |
Other, net |
|
(21 |
) |
|
|
(6 |
) |
Net cash from financing activities |
|
(965 |
) |
|
|
(1,071 |
) |
Effect of currency translation on cash |
|
25 |
|
|
|
25 |
|
Net change in cash and cash equivalents |
|
(108 |
) |
|
|
(207 |
) |
Cash and cash equivalents at beginning of period |
|
1,203 |
|
|
|
1,410 |
|
Cash and cash equivalents at end of period |
$ |
1,095 |
|
|
$ |
1,203 |
|
|
|
|
|
||||
|
|
|
|
||||
Non- |
|
|
|
||||
Cash flow from operating activities |
$ |
1,405 |
|
|
$ |
1,615 |
|
Additions to property, plant, and equipment (net) |
|
(551 |
) |
|
|
(689 |
) |
Non- |
$ |
854 |
|
|
$ |
926 |
|
Segment and Supplemental Comparable Basis Information (Unaudited) |
|||||||||||||||
|
Quarterly Period Ended |
||||||||||||||
(in millions of USD) |
Consumer
|
|
Consumer
|
|
Health,
|
|
Flexibles |
|
Total |
||||||
Net sales |
$ |
999 |
|
$ |
840 |
|
|
$ |
642 |
|
$ |
687 |
|
$ |
3,168 |
|
|
|
|
|
|
|
|
|
|
||||||
Operating income |
$ |
72 |
|
$ |
124 |
|
|
$ |
11 |
|
$ |
62 |
|
$ |
269 |
Depreciation and amortization |
|
82 |
|
|
56 |
|
|
|
47 |
|
|
32 |
|
|
217 |
Business consolidation and other activities |
|
29 |
|
|
(11 |
) |
|
|
20 |
|
|
14 |
|
|
52 |
Other non-cash charges |
|
3 |
|
|
2 |
|
|
|
1 |
|
|
2 |
|
|
8 |
Operating EBITDA |
$ |
186 |
|
$ |
171 |
|
|
$ |
79 |
|
$ |
110 |
|
$ |
546 |
|
|
|
|
|
|
|
|
|
|
|
Quarterly Period Ended |
||||||||||||||||
Reported net sales |
$ |
1,000 |
|
|
$ |
786 |
|
$ |
630 |
|
|
$ |
671 |
|
$ |
3,087 |
|
Foreign currency, acquisitions & divestitures |
|
(25 |
) |
|
|
14 |
|
|
(10 |
) |
|
|
1 |
|
|
(20 |
) |
Comparable net sales (1) |
$ |
975 |
|
|
$ |
800 |
|
$ |
620 |
|
|
$ |
672 |
|
$ |
3,067 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating income |
$ |
84 |
|
|
$ |
94 |
|
$ |
36 |
|
|
$ |
87 |
|
$ |
301 |
|
Depreciation and amortization |
|
80 |
|
|
|
58 |
|
|
45 |
|
|
|
29 |
|
|
212 |
|
Business consolidation and other activities |
|
18 |
|
|
|
7 |
|
|
2 |
|
|
|
1 |
|
|
28 |
|
Other non-cash charges |
|
2 |
|
|
|
2 |
|
|
1 |
|
|
|
1 |
|
|
6 |
|
Foreign currency, acquisitions & divestitures |
|
(0 |
) |
|
|
6 |
|
|
- |
|
|
|
- |
|
|
6 |
|
Comparable operating EBITDA (1) |
$ |
184 |
|
|
$ |
167 |
|
$ |
84 |
|
|
$ |
118 |
|
$ |
553 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year Ended |
||||||||||||||||
(in millions of USD) |
Consumer
|
|
Consumer
|
|
Health,
|
|
Flexibles |
|
Total |
||||||||
Net sales |
$ |
3,843 |
|
|
$ |
3,121 |
|
$ |
2,538 |
|
|
$ |
2,756 |
|
$ |
12,258 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating income |
$ |
186 |
|
|
$ |
366 |
|
$ |
75 |
|
|
$ |
310 |
|
$ |
937 |
|
Depreciation and amortization |
|
322 |
|
|
|
227 |
|
|
183 |
|
|
|
125 |
|
|
857 |
|
Business consolidation and other activities |
|
124 |
|
|
|
6 |
|
|
43 |
|
|
|
17 |
|
|
190 |
|
Other non-cash charges |
|
14 |
|
|
|
14 |
|
|
23 |
|
|
|
10 |
|
|
61 |
|
Operating EBITDA |
$ |
646 |
|
|
$ |
613 |
|
$ |
324 |
|
|
$ |
462 |
|
$ |
2,045 |
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ended |
||||||||||||||
Reported net sales |
$ |
4,031 |
|
|
$ |
3,122 |
|
$ |
2,627 |
|
$ |
2,884 |
|
$ |
12,664 |
Foreign currency, acquisitions & divestitures |
|
(16 |
) |
|
|
42 |
|
|
9 |
|
|
12 |
|
|
47 |
Comparable net sales (1) |
$ |
4,015 |
|
|
$ |
3,164 |
|
$ |
2,636 |
|
$ |
2,896 |
|
$ |
12,711 |
|
|
|
|
|
|
|
|
|
|
||||||
Operating income |
$ |
273 |
|
|
$ |
346 |
|
$ |
127 |
|
$ |
333 |
|
$ |
1,079 |
Depreciation and amortization |
|
310 |
|
|
|
217 |
|
|
177 |
|
|
114 |
|
|
818 |
Business consolidation and other activities |
|
50 |
|
|
|
23 |
|
|
22 |
|
|
7 |
|
|
102 |
Other non-cash charges |
|
25 |
|
|
|
12 |
|
|
8 |
|
|
9 |
|
|
54 |
Foreign currency, acquisitions & divestitures |
|
(2 |
) |
|
|
18 |
|
|
5 |
|
|
1 |
|
|
22 |
Comparable operating EBITDA (1) |
$ |
656 |
|
|
$ |
616 |
|
$ |
339 |
|
$ |
464 |
|
$ |
2,075 |
|
|
|
|
|
|
|
|
|
|
(1) |
The prior year comparable basis change excludes the impacts of foreign currency, acquisitions, and divestitures. Further details related to non-GAAP measures and reconciliations can be found under our “Non-GAAP Financial Measures and Estimates” section or in reconciliation tables in this release. |
Reconciliation of Non-GAAP Measures |
|||||||||||
Reconciliation of Net income and earnings per share (EPS) to adjusted operating income, operating earnings before interest, tax, depreciation and amortization (EBITDA), and adjusted earnings per share (adjusted EPS) (in millions of USD, except per share data amounts) |
|||||||||||
|
Quarterly Period Ended |
Fiscal Year Ended |
|||||||||
|
|
|
|
|
|||||||
Net income |
$ |
148 |
$ |
186 |
|
$ |
516 |
|
$ |
609 |
|
Add: other expense |
|
7 |
|
18 |
|
|
15 |
|
|
31 |
|
Add: interest expense |
|
86 |
|
78 |
|
|
311 |
|
|
306 |
|
Add: income tax expense |
|
28 |
|
19 |
|
|
95 |
|
|
133 |
|
Operating income |
$ |
269 |
$ |
301 |
|
$ |
937 |
|
$ |
1,079 |
|
|
|
|
|
|
|||||||
Add: business consolidation and other activities |
|
52 |
|
28 |
|
|
190 |
|
|
102 |
|
Add: Impact of hyperinflation |
|
— |
|
— |
|
|
15 |
|
|
— |
|
Add: other non-cash charges (1) |
|
8 |
|
6 |
|
|
46 |
|
|
54 |
|
Adjusted operating income (3) |
$ |
329 |
$ |
335 |
|
$ |
1,188 |
|
$ |
1,235 |
|
|
|
|
|
|
|||||||
Add: depreciation |
|
160 |
|
150 |
|
|
623 |
|
|
575 |
|
Add: amortization of intangibles |
|
57 |
|
62 |
|
|
234 |
|
|
243 |
|
Operating EBITDA (3) |
$ |
546 |
$ |
547 |
|
$ |
2,045 |
|
$ |
2,053 |
|
|
|
|
|
|
|||||||
Net income per diluted share |
$ |
1.26 |
$ |
1.55 |
|
$ |
4.38 |
|
$ |
4.95 |
|
Other expense, net |
|
0.06 |
|
0.15 |
|
|
0.13 |
|
|
0.25 |
|
Business consolidation and other activities |
|
0.44 |
|
0.23 |
|
|
1.61 |
|
|
0.83 |
|
Impact of hyperinflation |
|
— |
|
— |
|
|
0.13 |
|
|
— |
|
Amortization of intangibles from acquisitions (2) |
|
0.49 |
|
0.52 |
|
|
1.99 |
|
|
1.98 |
|
Income tax impact on items above |
|
0.02 |
|
(0.17 |
) |
|
(0.62 |
) |
|
(0.59 |
) |
Foreign currency, acquisitions, and divestitures |
|
|
0.01 |
|
|
|
0.05 |
|
|||
Adjusted net income per diluted share (3) |
$ |
2.27 |
$ |
2.29 |
|
$ |
7.62 |
|
$ |
7.47 |
|
|
|
|
|
|
|
Estimated Fiscal 2025 |
Cash flow from operating activities |
|
Net additions to property, plant, and equipment |
(525) |
Free cash flow (3) |
|
(1) |
Other non-cash charges are primarily stock compensation expense |
|
|
||
(2) |
Amortization of intangibles from acquisition are added back to better align our calculation of adjusted EPS with peers. |
|
|
||
(3) |
Supplemental financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in |
|
|
||
We define “free cash flow” as cash flow from operating activities, less net additions to property, plant, and equipment. We believe free cash flow is useful to an investor in evaluating our liquidity because free cash flow and similar measures are widely used by investors, securities analysts, and other interested parties in our industry to measure a company’s liquidity. We also believe free cash flow is useful to an investor in evaluating our liquidity as it can assist in assessing a company’s ability to fund its growth through its generation of cash. |
||
|
||
We also use Adjusted operating income, Operating EBITDA, adjusted EPS and comparable basis measures, among other measures, to evaluate management performance and in determining performance-based compensation. Operating EBITDA is a measure widely used by investors, securities analysts, and other interested parties in our industry to measure a company’s performance. We also believe EBITDA and Adjusted operating income are useful to an investor in evaluating our performance without regard to revenue and expense recognition, which can vary depending upon accounting methods. |
(BERY-F)
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119672933/en/
VP, Head of Investor Relations
+1 (812) 306 2964
ir@berryglobal.com
Source: